New NSAID for eyes
NPS' Australian Prescriber has provided a brief summary of the role of newly approved Ilevro (nepafenac), by Novartis, for prevention and treatment of pain and inflammation associated with cataract surgery.
After administration, nepafenac penetrates the cornea and is rapidly metabolised to amfenac by hydrolases, the article explains.
Nepafenac and amfenac work by potently inhibiting cyclo-oxygenase (COX) 1 and 2 enzymes.
Dosing is one drop per day for 15 days starting the day prior to surgery - go to nps.org.au for more.